How what we eat is destroying our livers, page-26

I think your over simplifying it Pav. Treatments for fatty liver will not be for everyone. Obviously only the seriously afflicted would require action as with any ailment. Being that there are over 7billion of us a tiny portion of the population will translate into RhT revenue. Morbidly obese must number in the 10s if not 100s of millions around the world. Read the article at the top of this thread. Pharma cos are surely sprinting to come up with an effective treatment.
I think your suggestion RHT management ran blind with hepafat development is your suggestion. They have years of relationships with the pharma/ medical community and would not commit to hepafat development without a fair idea of the expected outcome. My opinion.
Like I said before Ferriscan took many years to gain the market depth it has today- now it is regarded as gold standard. And it is making us money.